Tuesday , February 20 2018
Home / David L. Joffe, BSPharm, CDE, FACA (page 30)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA
(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

GLP-1: Actions on Beta-cell Mass and Function


David Joffe, BSPharm, CDE Tina Burge, PharmD Candidate Florida A&M University Kiet Ngo, Pharm D Candidate Mercer University Abnormalities in incretin hormones such as the glucagon-like peptide-1 (GLP-1) contribute to the development of hyperglycemia. GLP-1 was discovered as a peptide encoded by the proglucagon gene and was named glucagon-like because …

Read More »

DPP-4 Inhibitor Survey


During my frequent visits to prescribers’ offices I get a chance to see their prescribing habits. When it comes to DPP-4 inhibitors, medical professionals seem to have similar opinions on how to use each of the drugs from this class. But to test this theory, we contacted 25 primary care …

Read More »

Early Use of Insulin to Improve Beta Cell Preservation


By David Joffe, BSPharm, CDE; Steve Freed, BSPharm CPT; Brandon Flohr, PharmD, and Vanessa Cepero, PharmD, CVS Pharmacy Type 2 diabetes is a heterogeneous disorder, characterized by glucotoxicity, beta cell dysfunction and decreased insulin sensitivity. Presence of amyloid deposits in the islets and decreased beta cell mass are the pathological hallmark …

Read More »

BD NANO Pen Needle


    Reviewed by Dave Joffe, CDE, FACA, Editor-in-Chief and Katie Maneely, PharmD Intern, University of Florida   The new BD Nano Pen Needles are much smaller than the original BD needles. These new needles are both shorter (4mm) and thinner (32G) than standard needles, potentially offering a less painful way …

Read More »

What to tell your patients when they ask about Lantus and Cancer

David Joffe,BSPharm, CDE, FACA It has been over a week since Diabetologia released a meta-analysis of studies that possibly indicated that Lantus use is associatedwith cancer. During this time the lay press, television and cable news andhealth channels have pasted this all over the globe and many patients arecalling your …

Read More »

Drugs in Development

We often hear of new drugs, delivery methods and technologies for our patients. Unfortunately to often what seems like it will be approved next week can be years away if ever. I have done a wide search on some of the most talked about and publicized projects and have prepared …

Read More »


Last year when I first heard about the Flat-D pad, from Frank Morosky of FLAT-D innovations, I thought it was a joke. But after seeing some of the comments of users and doing some more research into why diabetes patients get gas, I now know why Frank called me. To …

Read More »